Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6485
    -0.0004 (-0.06%)
     

  • OIL

    82.75
    -0.61 (-0.73%)
     

  • GOLD

    2,341.70
    -0.40 (-0.02%)
     

  • Bitcoin AUD

    99,890.27
    -2,689.27 (-2.62%)
     

  • CMC Crypto 200

    1,401.81
    -22.29 (-1.57%)
     

  • AUD/EUR

    0.6069
    +0.0012 (+0.20%)
     

  • AUD/NZD

    1.0949
    +0.0019 (+0.17%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,505.89
    +34.42 (+0.20%)
     

  • FTSE

    8,041.07
    -3.74 (-0.05%)
     

  • Dow Jones

    38,339.25
    -164.44 (-0.43%)
     

  • DAX

    18,068.75
    -68.90 (-0.38%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

Business Wire
·1-min read

VANCOUVER, British Columbia, May 29, 2023--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California on Tuesday, June 13, 2023, at 1:20 p.m. Pacific Time (4:20 p.m. Eastern Time).

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005760/en/

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com, +1(778)729-9116